Accessibility Menu
Exelixis logo

Exelixis(NASDAQ) EXEL

Market Cap$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+256%
5 Year+213%
1 Year+45%
1 Month-4%
$54.09
+3.62%
+1.89Today
After hours$54.10+$0.01 (+0.02%)
Exelixis last closing stock price
MetricPriceDate
Last closeUSD 54.072026-08-07
Exelixis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.96%USD 53.032026-07-31
1 month-3.64%USD 56.112026-07-08
3 month+12.27%USD 48.162026-05-08
Year to date+23.36%USD 43.832025-12-31
1 year+44.61%USD 37.392025-08-07
3 year+163.76%USD 20.502023-08-08
5 year+213.45%USD 17.252021-08-06
Since inception+256.02%USD 15.192000-04-11

Exelixis Financials at a Glance

Market Cap

$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.44B

Net Income (TTM)

$860.62M

EPS (TTM)

$3.18

P/E Ratio

16.98

Dividend

$0.00

Beta (Volatility)

0.61 (Low)

Price

$54.09

Volume

3,550,012.616

Open

$52.69

Previous Close

$54.07

Daily Range

$52.17 - $54.14

52-Week Range

$33.76 - $57.57

Estimated Earnings Date

Nov 3, 2026

EXEL News

A biotech lab technician using multiple pipettes to load blood samples into test tubes.

5 Best Biotech Stocks for 2026 and How to Invest

Keith SpeightsJul 17, 2026
Exelixis logo

Prediction: This Stock Could Double By 2031

Prosper Junior BakinyMay 15, 2026
mqdefault - 2026-03-26T080435.868

Exelixis: A Strong Contender in the Cancer Drug Market

Motley Fool YouTubeMar 31, 2026
exelixis

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

James HalleyFeb 28, 2026
Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in SPDR S&P Biotech ETF (XBI)

Rachel WarrenFeb 25, 2026
Doctor and patient in a hospital room.

Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026

Prosper Junior BakinyFeb 20, 2026
Person raising two fists in the air.

2 Stocks That Could Soar This Year

Prosper Junior BakinyJan 31, 2026
Patient sitting on hospital bed.

The Ultimate Biotech Stock to Buy With $50 Right Now

Prosper Junior BakinyOct 14, 2025
Page 1

EXEL: Motley Fool Moneyball Superscore

79

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Exelixis

Exelixis develops medicines that help people with advanced cancers live longer. Its main drugs treat kidney, liver, and thyroid cancers. These medicines are used by doctors to manage difficult cancer cases.

What’s in the Exelixis Medicine Cabinet?

  • Cabozantinib Franchise (CABOMETYX, COMETRIQ): Tablets and capsules for advanced kidney, liver, and thyroid cancers; 99% of product revenue in 2024; used by oncologists for patients needing new treatment options.
  • COTELLIC: Oral drug for advanced melanoma (skin cancer); marketed by Genentech; generates profit share and royalties for Exelixis.
  • MINNEBRO: Blood pressure medicine for hypertension in Japan; marketed by Daiichi Sankyo; Exelixis receives royalties.
  • Pipeline Programs: New cancer drugs in clinical trials, including zanzalintinib and several early-stage therapies; aim to treat a wider range of solid tumors.

Growth Moves: The Exelixis Expansion Playbook

  • Formed global partnerships with Ipsen (Europe, 2016) and Takeda (Japan, 2017) to commercialize cabozantinib outside the U.S.
  • Launched CABOMETYX in new cancer types and geographies from 2016 to 2024, expanding its market reach.
  • Entered collaborations with Genentech (COTELLIC) and Daiichi Sankyo (MINNEBRO) to diversify revenue streams.
  • Expanded research pipeline through licensing deals with companies like Redwood Bioscience and Aurigene Discovery Technologies.
  • Authorized $500 million stock repurchase program in 2024, following $450 million completed buyback.

What Makes Exelixis Stand Out?

Exelixis controls drug discovery, development, and sales, giving it flexibility and speed. Its main drug, cabozantinib, is a standard treatment for advanced kidney cancer. The company relies on global partners to reach patients outside the U.S. and invests heavily in new cancer therapies.

Five Things You Need to Know

  • Total revenue was $2.17 billion in 2024, up 18% from 2023.
  • CABOMETYX made up 99% of product revenue in 2024, rising 11% year-over-year.
  • Net income reached $521 million in 2024, up 151% from 2023.
  • Operating cash flow was $700 million in 2024, up 110% from 2023.

Bottom Line

Exelixis has grown by focusing on cancer drugs and expanding through partnerships. Its strong cash flow and pipeline investments support ongoing adaptation in a competitive market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,077

CEO

Michael M. Morrissey, PhD

Website

www.exelixis.com

Headquarters

Alameda, CA 94502, US

EXEL Financials

Key Financial Metrics (TTM)

Gross Margin

96.48%

Operating Margin

39.88%

Net Income Margin

35.33%

Return on Equity

42.49%

Return on Capital

37.36%

Return on Assets

34.50%

Earnings Yield

5.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

247.78M

Volume

3.55M

Avg. Volume

2.67M

Financials (TTM)

Gross Profit

$2.35B

Operating Income

$971.51M

EBITDA

$1.04B

Operating Cash Flow

$1.44B

Capital Expenditure

-$4.67M

Free Cash Flow

$1.43B

Cash & ST Invst.

$839.39M

Total Debt

$165.93M

Exelixis Performance Analysis

Exelixis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,611,062,00012.3%
20232023-12-31USD 1,830,208,00013.6%
20242024-12-31USD 2,168,701,00018.5%
20252025-12-31USD 2,320,126,0007.0%
Exelixis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-035.2%
Q42026-01-020.2%
Q12026-04-032.0%
Q22026-07-032.9%
Exelixis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.56-21.7%
20232023-12-31USD 0.6515.1%
20242024-12-31USD 1.76172.4%
20252025-12-31USD 2.7857.7%
Exelixis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-037.7%
Q42026-01-0225.7%
Q12026-04-03-10.2%
Q22026-07-033.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$628.69M

+10.6%

Gross Profit

$608.03M

+10.8%

Gross Margin

96.71%

N/A

Market Cap

$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.44M

N/A

Employees

1,077

N/A

Net Income

$212.05M

+14.7%

EBITDA

$262.68M

+10.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$839.39M

+6.1%

Total Debt

$165.93M

-7.7%

Accounts Receivable

$322.21M

+10.2%

Inventory

$28.73M

+22.3%

Long Term Debt

$165.93M

-7.7%

Short Term Debt

$0.00

N/A

Return on Assets

34.50%

N/A

Return on Invested Capital

45.56%

N/A

Free Cash Flow

$559.59M

+1132.4%

Operating Cash Flow

$559.59M

+1042.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALGNAlign Technology, Inc.
$173.66+2.71%
BMRNBioMarin Pharmaceutical Inc.
$63.81+3.82%
HALOHalozyme Therapeutics, Inc.
$103.12+20.24%
MDGLMadrigal Pharmaceuticals, Inc.
$510.04-0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About EXEL

What is the current price of Exelixis?

Exelixis is trading at $54.07 per share.

What is the 52-week range for Exelixis?

Over the past 52 weeks, Exelixis has traded between $33.76 and $57.57.

How much debt does Exelixis have?

As of the most recent reporting period, Exelixis reported total debt of $165.93M.

How much cash does Exelixis have on hand?

Exelixis reported $225.56M in cash and cash equivalents in its most recent financial results.

What is Exelixis’s dividend yield?

Exelixis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services